Results 271 to 280 of about 179,384 (308)

Study Protocol for HeartMagic: A Prospective Observational Cohort Characterizing Subtypes of Heart Failure With Preserved Ejection Fraction. [PDF]

J Am Heart Assoc
Meyer P, Rocca A, Banus J, Ogier AC, Georgantas C, Calarnou P, Fatima A, Vallée JP, Deux JF, Thomas A, Marquis J, Monney P, Lu H, Porretta AP, Ledoux JB, Tillier C, Crowe LA, Abdurashidova T, Richiardi J, Hullin R, van Heeswijk RB.   +20 more
europepmc   +1 more source

Cardiac resynchronization therapy and pulmonary artery banding in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block

Pediatric Investigation, EarlyView.
The combination of cardiac resynchronization therapy and pulmonary artery banding was associated with substantial improvement in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block. Most patients exhibited marked improvement in clinical status and ventricular function, along with a reduction in QRS ...
Min Zeng, Fan Yang, Quanlin Li, Kai Ma, Zheng Dou, Kunjing Pang, Xinjie Lin, Shoujun Li, Xu Wang   +8 more
wiley   +1 more source

Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation. [PDF]

J Arrhythm
Sawada M, Watanabe R, Nagashima K, Saito Y, Wakamatsu Y, Otsuka N, Hori K, Hirata S, Hirata M, Okumura Y.   +9 more
europepmc   +1 more source

6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis

Phytotherapy Research, EarlyView.
Doxorubicin induces cardiac and skeletal muscle atrophy by upregulating E3 ubiquitin ligases, inhibiting myogenic regulatory factors, and activating necroptosis. Cardiac atrophy can further exacerbate cardiotoxicity. 6‐Shogaol negatively regulates these processes and attenuates doxorubicin‐induced cardiac and skeletal muscle atrophy.
Xipeng Sun, Yaxian Wang, Quanjun Yang, Bo Xin, Jinlu Huang, Cheng Guo   +5 more
wiley   +1 more source

Circulating oxylipins predict mortality in heart failure with preserved ejection fraction. [PDF]

ESC Heart Fail
Aradhyula V, Manandhar S, Sherafati A, Kloster A, Fares A, Dube P, Brewster PS, Moukarbel GV, Maddipati KR, Haller ST, Kennedy DJ, Gupta R, Khouri SJ.   +12 more
europepmc   +1 more source

Development and external validation of a sarcopenia risk prediction model in elderly patients with heart failure with preserved ejection fraction. [PDF]

BMC Geriatr
Yang Q, Jiang Q, Bai T, Zhu Y, Zhao Y, Xu G, Wu F, Cui P, Li F.   +8 more
europepmc   +1 more source

Obesity-Related Asian Patients With Heart Failure With Preserved Ejection Fraction. [PDF]

JACC Asia
Kagami K, Yuasa N, Harada T, Kondo T, Murakami T, Yoshino S, Yamada E, Wada N, Ishii H, Obokata M.   +9 more
europepmc   +1 more source

Change in dapagliflozin trial eligibility status and prognosis among patients with acute heart failure with preserved ejection fraction. [PDF]

J Chin Med Assoc
Ling LC, Huang WM, Chang HC, Lee CW, Yu WC, Cheng HM, Chiang CE, Chen CH, Sung SH.   +8 more
europepmc   +1 more source

Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery. [PDF]

Int J Mol Sci
Kim T, Sheen M, Ryan D, Joseph J.
europepmc   +1 more source